Non-Hodgkin Lymphoma (NHL)
Oncology·MeSH: Lymphoma, Non-Hodgkin
Prevalence
30.0 / 100K
6 drugs in development·5 companies·2 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| belrapzo | EAGLE PHARMACEUTICALS, INC. (EGRX) |
Phase 3(1)
| Drug | Company |
|---|---|
| jcar017 | Juno Therapeutics, Inc. (JUNO) |
Phase 2(2)
Phase 1(1)
| Drug | Company |
|---|---|
| mb-106 | MUSTANG BIO, INC. (MBIO) |
Phase 1/Phase 2(1)
Compare drugs
Frequently asked questions
How many drugs are in development for Non-Hodgkin Lymphoma (NHL)?
BioSniper tracks 6 drugs in development for Non-Hodgkin Lymphoma (NHL) across 5 companies.
How many clinical trials target Non-Hodgkin Lymphoma (NHL)?
There are 2 clinical trials targeting Non-Hodgkin Lymphoma (NHL) tracked by BioSniper.
What is the prevalence of Non-Hodgkin Lymphoma (NHL)?
The estimated prevalence of Non-Hodgkin Lymphoma (NHL) is approximately 30.0 per 100,000 population.
Deep-dive into Non-Hodgkin Lymphoma (NHL)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis